Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program

Fig. 3

VEGF-specific IgG subclasses between weeks 6–12, 16–48, 49–96 and 97–144. The study was made for the available serum samples classified as positive for VEGF-specific IgG antibodies. “n” represents the number of the available serum samples. Terms “non-detectable”, “detectable” and “predominant” are detailed in Methods

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us